未登录 A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial 一项关于阿替利珠单抗、贝伐珠单抗和化疗在获得性耐药的EGFR突变非小细胞肺癌中的随机非对照II期研究——ETOP 15-19 ABC-lung试验 Soo, R. A.; Vervita, K.; Fruh, M.; Cho, B. C.; Majem, M.; Abreu, D. Rodriguez; Ribi, K.; Callejo, A.; Moran, T.; Gomez, M. Domine; Provencio, M.; Addeo, A.; Han, J. Y.; Granados, A. L. Ortega; Reck, M.; Blasco, A.; Campelo, R. Garcia; Gonzalez, M. A. Sala; Britschgi, C.; Roschitzki-Voser, H.; Ruepp, B.; Gasca-Ruchti, A.; Haberecker, M.; Dafni, U.; Peters, S.; Stahel, R. A. 分享 收藏
Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation Peters, S.; Loi, S.; Andre, F.; Chandarlapaty, S.; Felip, E.; Finn, S. P.; Janne, P. A.; Kerr, K. M.; Munzone, E.; Passaro, A.; Perol, M.; Smit, E. F.; Swanton, C.; Viale, G.; Stahel, R. A. 分享 收藏
ESMO Guidance for Reporting Oncology real-World evidence (GROW) 报告肿瘤学真实世界证据的ESMO指南 (GROW) Castelo-Branco, L.; Pellat, A.; Martins-Branco, D.; Valachis, A.; Derksen, J. W. G.; Suijkerbuijk, K. P. M.; Dafni, U.; Dellaporta, T.; Vogel, A.; Prelaj, A.; Groenwold, R. H. H.; Martins, H.; Stahel, R.; Bliss, J.; Kather, J.; Ribelles, N.; Perrone, F.; Hall, P. S.; Dienstmann, R.; Booth, C. M.; Pentheroudakis, G.; Delaloge, S.; Koopman, M. 分享 收藏
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma PD-1-expressing巨噬细胞和CD8 T细胞是晚期间皮瘤PD-1抑制临床获益的独立预测因子 Homicsko, Krisztian; Zygoura, Panagiota; Norkin, Maxim; Tissot, Stephanie; Shakarishvili, Nicholas; Popat, Sanjay; Curioni-Fontecedro, Alessandra; O'Brien, Mary; Pope, Anthony; Shah, Riyaz; Fisher, Patricia; Spicer, James; Roy, Amy; Gilligan, David; Rusakiewicz, Sylvie; Fortis, Ekaterina; Marti, Nesa; Kammler, Roswitha; Finn, Stephen P.; Coukos, Georges; Dafni, Urania; Peters, Solange; Stahel, Rolf A. 分享 收藏
Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial Girard, N.; Aix, S. Ponce; Cedres, S.; Berghmans, T.; Burgers, S.; Toffart, A-C; Popat, S.; Janssens, A.; Gervais, R.; Hochstenbag, M.; Silva, M.; Burger, I. A.; Prosch, H.; Stahel, R.; Xenophontos, E.; Pretzenbaher, Y.; Neven, A.; Peters, S. 分享 收藏
Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project (vol 35, pg 1888, 2022) 间皮瘤患者中磷酸化核糖体蛋白S6的表达-与临床病理特征和结果的相关性: 来自欧洲胸部肿瘤学平台 (ETOP) Mesoscape项目的结果 (第35卷，1888页，2022) Ruschoff, Jan Hendrik; Haberecker, Martina; Tsourti, Zoi; Nackaerts, Kristiaan; de Perrot, Marc; Brcic, Luka; Nadal, Ernest; Tsimpoukis, Sotirios; Gray, Steven G.; Ampollini, Luca; Aerts, Joachim G.; Felley-Bosco, Emanuela; Kirschner, Michaela B.; Monkhorst, Kim; Weynand, Birgit; Bavaghar-Zaeimi, Fatemeh; Samarzija, Miroslav; Llatjos, Roger; Finn, Stephen P.; Silini, Enrico; von der Thusen, Jan; Marti, Nesa; Vervita, Karerina; Kammler, Roswitha; Peters, Solange; Stahel, Rolf A.; Baas, Paul; Opitz, Isabelle 分享 收藏
Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma Sun, Suna; Qi, Weihong; Rehrauer, Hubert; Ronner, Manuel; Hariharan, Ananya; Wipplinger, Martin; Meiller, Clement; Stahel, Rolf; Fruh, Martin; Cerciello, Ferdinando; Fonteneau, Jean-Francois; Jean, Didier; Felley-Bosco, Emanuela 分享 收藏
Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project 间皮瘤患者中磷酸化核糖体蛋白S6的表达-与临床病理特征和结果的相关性: 来自欧洲胸部肿瘤学平台 (ETOP) Mesoscape项目的结果 Rueschoff, Jan Hendrik; Haberecker, Martina; Tsourti, Zoi; Nackaerts, Kristiaan; de Perrot, Marc; Brcic, Luka; Nadal, Ernest; Tsimpoukis, Sotirios; Gray, Steven G.; Ampollini, Luca; Aerts, Joachim G.; Felley-Bosco, Emanuela; Kirschner, Michaela B.; Monkhorst, Kim; Weynand, Birgit; Bavaghar-Zaeimi, Fatemeh; Samarzija, Miroslav; Llatjos, Roger; Finn, Stephen P.; Silini, Enrico; von der Thusen, Jan; Marti, Nesa; Vervita, Karerina; Kammler, Roswitha; Peters, Solange; Stahel, Rolf A.; Baas, Paul; Opitz, Isabelle 分享 收藏
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis Dafni, U.; Soo, R. A.; Peters, S.; Tsourti, Z.; Zygoura, P.; Vervita, K.; Han, J-Y; De Castro, J.; Coate, L.; Fruh, M.; Hashemi, S. M. S.; Nadal, E.; Carcereny, E.; Sala, M. A.; Bernabe, R.; Provencio, M.; Cuffe, S.; Roschitzki-Voser, H.; Ruepp, B.; Rosell, R.; Stahel, R. A. 分享 收藏
Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data Perol, M.; Felip, E.; Dafni, U.; Polito, L.; Pal, N.; Tsourti, Z.; Ton, T. G. N.; Merritt, D.; Morris, S.; Stahel, R.; Peters, S. 分享 收藏
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial 奥希替尼和贝伐单抗与单独奥希替尼作为二线靶向治疗的二线随机II期研究证实EGFR和获得性T790M突变的晚期NSCLC: 欧洲胸部肿瘤学平台 (ETOP 10-16) 加强试验 Sooy, R. A.; Han, J. -Y.; Dafni, U.; Cho, B. C.; Yeo, C. M.; Nadal, E.; Carcereny, E.; de Castro, J.; Sala, M. A.; Bernabe, R.; Coate, L.; Provencio Pulla, M.; Campelo, R. Garcia; Cuffe, S.; Hashemi, S. M. S.; Fruh, M.; Massuti, B.; Garcia-Sanchez, J.; Domine, M.; Majem, M.; Sanchez-Torres, J. -M.; Britschgi, C.; Pless, M.; Dimopoulou, G.; Roschitzki-Voser, H.; Ruepp, B.; Rosell, R.; Stahel, R. A.; Peters, S. 分享 收藏
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial Peters, S.; Pujol, J-L; Dafni, U.; Domine, M.; Popat, S.; Reck, M.; Andrade, J.; Becker, A.; Moro-Sibilot, D.; Curioni-Fontecedro, A.; Molinier, O.; Nackaerts, K.; Molla, A. Insa; Gervais, R.; Lopez Vivanco, G.; Madelaine, J.; Mazieres, J.; Faehling, M.; Griesinger, F.; Majem, M.; Gonzalez Larriba, J. L.; Provencio Pulla, M.; Vervita, K.; Roschitzki-Voser, H.; Ruepp, B.; Mitchell, P.; Stahel, R. A.; Le Pechoux, C.; De Ruysscher, D. 分享 收藏
EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours Le Rhun, E.; Guckenberger, M.; Smits, M.; Dummer, R.; Bachelot, T.; Sahm, F.; Galldiks, N.; de Azambuja, E.; Berghoff, A. S.; Metellus, P.; Peters, S.; Hong, Y-K; Winkler, F.; Schadendorf, D.; van den Bent, M.; Seoane, J.; Stahel, R.; Minniti, G.; Wesseling, P.; Weller, M.; Preusser, M. 分享 收藏
Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial Girard, N.; Ponce Aix, S.; Cedres, S.; Berghmans, T.; Burgers, S.; Toffart, A. C.; Popat, S.; Janssens, A.; Gervais, R.; Hochstenbag, M.; Silva, M.; Burger, I.; Prosch, H.; Stahel, R. A.; Govaerts, A-S.; Pochesci, A.; Neven, A.; Peters, S. 分享 收藏
Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial Hiltbrunner, S.; Britschgi, C.; Schuberth, P.; Bankel, L.; Nguyen-Kim, T. D. L.; Gulati, P.; Weder, W.; Opitz, I.; Lauk, O.; Caviezel, C.; Bachmann, H.; Tabor, A.; Schroder, P.; Knuth, A.; Munz, C.; Stahel, R.; Boyman, O.; Renner, C.; Petrausch, U.; Curioni-Fontecedro, A. 分享 收藏
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial Popat, S.; Curioni-Fontecedro, A.; Dafni, U.; Shah, R.; O'Brien, M.; Pope, A.; Fisher, P.; Spicer, J.; Roy, A.; Gilligan, D.; Gautschi, O.; Nadal, E.; Janthur, W. D.; Castro, R. Lopez; Campelo, R. Garcia; Rusakiewicz, S.; Letovanec, I; Polydoropoulou, V; Roschitzki-Voser, H.; Ruepp, B.; Gasca-Ruchti, A.; Peters, S.; Stahel, R. A. 分享 收藏
The Impact on Outcome by Adding Bevacizumab to Standard Induction Chemotherapy Prior to Mesothelioma Surgery: A Retrospective Single Center Analysis Lauk, Olivia; Bruestle, Karina; Neuer, Thomas; Battilana, Bianca; Nguyen, Thi Dan Linh; Frauenfelder, Thomas; Stahel, Rolf; Weder, Walter; Curioni-Fontecedro, Alessandra; Opitz, Isabelle 分享 收藏
Verification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural Mesothelioma Cerciello, Ferdinando; Choi, Meena; Sinicropi-Yao, Sara L.; Lomeo, Katie; Amann, Joseph M.; Felley-Bosco, Emanuela; Stahel, Rolf A.; Robinson, Bruce W. S.; Creaney, Jenette; Pass, Harvey, I; Vitek, Olga; Carbone, David P. 分享 收藏
Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial Peters, S.; Pujol, J-L.; Dafni, U.; Domine, M.; Becker, A.; Andrade, J.; Curioni-Fontecedro, A.; Molinier, O.; Moro-Sibilot, D.; Nackaerts, K.; Insa Molla, A.; Lopez Vivanco, G.; Madelaine, J.; Popat, S.; Reck, M.; Roschitzki-Voser, H.; Mitchell, P.; De Ruysscher, D.; Le Pechoux, C.; Stahel, R. 分享 收藏
Immunotherapy, chemotherapy and stereotactic radiotherapy to metastases, followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic NSCLC: The ETOP CHESS trial Guckenberger, M.; Opitz, I.; Dafni, U.; Fontecedro, A. Curioni; Scherz, A.; Elicin, O.; Addeo, A.; Aerts, J. G. J. V.; Dingemans, A-M.; Hendriks, L.; Jimenez Munarriz, B.; Juan-Vidal, O.; Sullivan, I.; Valdivia, J.; Piguet, A-C.; Roschitzki-Voser, H.; Ehrbar, S.; Baumgartl, M.; Peters, S.; Stahel, R. A. 分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
MODERN PATHOLOGY.png)
OAAI
.png){kind=icon}
分享.png){kind=icon}
收藏